Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply
- PMID: 33933201
- DOI: 10.1016/S0140-6736(21)00271-3
Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply
Conflict of interest statement
We declare no competing interests.
Comment on
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.Lancet. 2020 Nov 14;396(10262):1563-1573. doi: 10.1016/S0140-6736(20)32292-3. Lancet. 2020. PMID: 33189178 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
